E-viri
Recenzirano
Odprti dostop
-
Van Hees, S.; Bourgeois, S.; Van Vlierberghe, H.; Sersté, T.; Francque, S.; Michielsen, P.; Sprengers, D.; Reynaert, H.; Henrion, J.; Negrin Dastis, S.; Delwaide, J.; Lasser, L.; Decaestecker, J.; Orlent, H.; Janssens, F.; Robaeys, G.; Colle, I.; Stärkel, P.; Moreno, C.; Nevens, F.; Vanwolleghem, T.; Van Hees, Stijn; Bourgeois, Stefan; Van Vlierberghe, Hans; Sersté, Thomas; Francque, Sven; Michielsen, Peter; Sprengers, Dirk; Reynaert, Hendrik; Henrion, Jean; Negrin‐Dastis, Sergio; Delwaide, Jean; Lasser, Luc; Decaestecker, Jochen; Orlent, Hans; Janssens, Filip; Robaeys, Geert; Colle, Isabelle; Stärkel, Peter; Moreno, Christophe; Nevens, Frederik; Vanwolleghem, Thomas
Alimentary pharmacology & therapeutics, April 2018, Letnik: 47, Številka: 8Journal Article
Summary Background Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis B infections differ substantially between distinct ethnicities. Aim The aim of this study was to determine relapse rates, factors predicting relapse and clinical outcomes after nucleos(t)ide analogue cessation in a large, predominantly Caucasian cohort of chronic hepatitis B patients with nucleos(t)ide analogue‐induced HBeAg seroconversion. Methods This is a nationwide observational cohort study including HBeAg positive, mono‐infected chronic hepatitis B patients with nucleos(t)ide analogue‐induced HBeAg seroconversion from 18 centres in Belgium. Results A total of 98 patients with nucleo(s)tide analogue‐induced HBeAg seroconversion were included in the study. Of the 62 patients who stopped treatment after a median consolidation treatment of 8 months, 30 relapsed. Higher gamma‐glutamyl transferase levels at both treatment initiation (HR 1.004; P = 0.001 per unit increment) and HBeAg seroconversion (HR 1.006; P = 0.013 per unit increment) were associated with an increased risk of clinically significant relapse in a multivariate Cox regression model. Treatment cessation led to liver‐related death in 2 patients, of whom one showed a severe flare. Of the patients who continued treatment after HBeAg seroconversion, none relapsed or developed severe hepatic outcomes. Conclusion Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos(t)ide analogue‐induced HBeAg seroconversion results in viral relapses in more than half of patients with potential fatal outcomes. These real‐world data further lend support to preferentially continue NA treatment after HBeAg seroconversion until HBsAg loss. Linked ContentThis article is linked to Ingiliz and Canbay paper. To view this article visit https://doi.org/10.1111/apt.14649.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.